TY - JOUR
T1 - Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia
AU - Johnson, Royce H.
AU - Levine, Stephanie
AU - Traub, Scott L.
AU - Echols, Roger M.
AU - Haverstock, Daniel
AU - Arnold, Erika
AU - Kowalsky, Steven F.
PY - 1996
Y1 - 1996
N2 - The efficacy and safety of sequential (intravenous/oral) ciprofloxacin were compared with the efficacy and safety of ceftriaxone for the treatment of hospitalized patients with acute bacterial pneumonia. In this prospective, controlled, double-blind, randomized multicenter trial, 227 patients were enrolled and received either intravenous ciprofloxacin (400 mg every 12 hours) followed by oral ciprofloxacin (500 mg every 12 hours) or intravenous ceftriaxone followed by intramuscular ceftriaxone (1 g every 24 hours). Ninety-six patients (50, ciprofloxacin; 46, ceftriaxone) were valid for efficacy; 91% had community-acquired pneumonia. Clinical cure, observed in 44 (90%) of 49 ciprofloxacin patients and in 38 (84%) of 45 ceftriaxone patients, was statistically equivalent for the two treatment groups, using a 95% confidence interval (CI) = -0.092, 0.198. Bacteriologic eradication was effective for 45 (94%) of 48 ciprofloxacin patients and for 42 (100%) of 42 ceftriaxone patients (95% CI = -0.189, 0.074). Both ciprofloxacin and ceftriaxone were effective in eradicating Streptococcus pneumoniae organisms in 21 (91%) of 23 patients and 17 (100%) of 17 patients, respectively; Haemophilus influenzae organisms in 18 of 18 patients and 8 of 8 patients, respectively; and Moraxella catarrhalis organisms in 4 of 4 patients and 2 of 2 patients, respectively. Both treatments were well tolerated, although ciprofloxacin had a higher rate of injection site reactions than ceftriaxone (10% and 3%, respectively) (P = .024). This study is the first demonstrating sequential ciprofloxacin therapy to be as safe and effective as parenteral ceftriaxone in the treatment of hospitalized patients with pneumonia.
AB - The efficacy and safety of sequential (intravenous/oral) ciprofloxacin were compared with the efficacy and safety of ceftriaxone for the treatment of hospitalized patients with acute bacterial pneumonia. In this prospective, controlled, double-blind, randomized multicenter trial, 227 patients were enrolled and received either intravenous ciprofloxacin (400 mg every 12 hours) followed by oral ciprofloxacin (500 mg every 12 hours) or intravenous ceftriaxone followed by intramuscular ceftriaxone (1 g every 24 hours). Ninety-six patients (50, ciprofloxacin; 46, ceftriaxone) were valid for efficacy; 91% had community-acquired pneumonia. Clinical cure, observed in 44 (90%) of 49 ciprofloxacin patients and in 38 (84%) of 45 ceftriaxone patients, was statistically equivalent for the two treatment groups, using a 95% confidence interval (CI) = -0.092, 0.198. Bacteriologic eradication was effective for 45 (94%) of 48 ciprofloxacin patients and for 42 (100%) of 42 ceftriaxone patients (95% CI = -0.189, 0.074). Both ciprofloxacin and ceftriaxone were effective in eradicating Streptococcus pneumoniae organisms in 21 (91%) of 23 patients and 17 (100%) of 17 patients, respectively; Haemophilus influenzae organisms in 18 of 18 patients and 8 of 8 patients, respectively; and Moraxella catarrhalis organisms in 4 of 4 patients and 2 of 2 patients, respectively. Both treatments were well tolerated, although ciprofloxacin had a higher rate of injection site reactions than ceftriaxone (10% and 3%, respectively) (P = .024). This study is the first demonstrating sequential ciprofloxacin therapy to be as safe and effective as parenteral ceftriaxone in the treatment of hospitalized patients with pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=0029951922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029951922&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029951922
SN - 1056-9103
VL - 5
SP - 265
EP - 272
JO - Infectious Diseases in Clinical Practice
JF - Infectious Diseases in Clinical Practice
IS - 4
ER -